Signant Health expands availability of its eClinical solutions by joining IQVIA One Home for Sites initiative
Signant Health, a leader in clinical trial evidence generation, has joined IQVIA's One Home for Sites™ initiative. This collaboration aims to simplify clinical research by providing a single sign-on platform for sites to access multiple eClinical technologies. Signant's SmartSignals® Unified Platform, which includes eCOA, EDC, RTSM, eConsent, and telemedicine, will be available through One Home for Sites.
Sanjiv Waghmare, Signant's chief product officer, expressed enthusiasm for the partnership, noting its alignment with Signant's strategy to provide unified access to their products. Melissa Easy, VP of Commercialization for IQVIA Technologies, welcomed Signant's contribution to building a next-generation clinical trial ecosystem that benefits all stakeholders, particularly patients.
Signant Health, un leader nella generazione di prove di studi clinici, ha aderito all'iniziativa One Home for Sites™ di IQVIA. Questa collaborazione mira a semplificare la ricerca clinica fornendo una piattaforma di accesso unificato per i siti, permettendo l'accesso a molteplici tecnologie eClinical. La piattaforma unificata SmartSignals® di Signant, che include eCOA, EDC, RTSM, eConsent e telemedicina, sarà disponibile tramite One Home for Sites.
Sanjiv Waghmare, chief product officer di Signant, ha espresso entusiasmo per la partnership, sottolineando la sua coerenza con la strategia di Signant di fornire accesso unificato ai propri prodotti. Melissa Easy, VP della Commercializzazione per IQVIA Technologies, ha accolto il contributo di Signant nella costruzione di un ecosistema di studi clinici di nuova generazione che avvantaggia tutti i portatori di interesse, in particolare i pazienti.
Signant Health, un líder en la generación de pruebas de ensayos clínicos, se ha unido a la iniciativa One Home for Sites™ de IQVIA. Esta colaboración tiene como objetivo simplificar la investigación clínica proporcionando una plataforma de inicio de sesión único para que los sitios accedan a múltiples tecnologías eClinical. La plataforma unificada SmartSignals® de Signant, que incluye eCOA, EDC, RTSM, eConsent y telemedicina, estará disponible a través de One Home for Sites.
Sanjiv Waghmare, director de productos de Signant, expresó su entusiasmo por la asociación, señalando su alineación con la estrategia de Signant para proporcionar acceso unificado a sus productos. Melissa Easy, VP de Comercialización de IQVIA Technologies, dio la bienvenida a la contribución de Signant en la construcción de un ecosistema de ensayos clínicos de próxima generación que beneficie a todos los interesados, especialmente a los pacientes.
Signant Health는 임상 시험 증거 생성의 선두 주자로서 IQVIA의 One Home for Sites™ 이니셔티브에 참여하게 되었습니다. 이 협력은 연구 사이트가 다양한 eClinical 기술에 접근할 수 있는 단일 로그인 플랫폼을 제공하여 임상 연구를 간소화하는 것을 목표로 하고 있습니다. Signant의 SmartSignals® 통합 플랫폼은 eCOA, EDC, RTSM, eConsent 및 원격의료를 포함하며, One Home for Sites를 통해 제공될 예정입니다.
Signant의 최고 제품 책임자인 Sanjiv Waghmare는 이 파트너십에 대한 열정을 표명하며, 이는 Signant의 제품에 대한 통합 접근을 제공하려는 전략과 일치한다고 언급했습니다. IQVIA Technologies의 상업화 부사장인 Melissa Easy는 모든 이해 관계자에게 이익을 주는 차세대 임상 시험 생태계를 구축하는 데 Signant의 기여를 환영했습니다. 특히, 환자에게 혜택이 돌아가도록 하였습니다.
Signant Health, un leader dans la génération de preuves d'essais cliniques, a rejoint l'initiative One Home for Sites™ d'IQVIA. Cette collaboration vise à simplifier la recherche clinique en fournissant une plateforme de connexion unique pour que les sites accèdent à plusieurs technologies eClinical. La plateforme unifiée SmartSignals® de Signant, qui inclut eCOA, EDC, RTSM, eConsent et télémédecine, sera disponible via One Home for Sites.
Sanjiv Waghmare, directeur produit de Signant, a exprimé son enthousiasme pour ce partenariat, soulignant son alignement avec la stratégie de Signant de fournir un accès unifié à ses produits. Melissa Easy, VP de la commercialisation pour IQVIA Technologies, a salué la contribution de Signant à la construction d'un écosystème d'essais cliniques de nouvelle génération qui profite à toutes les parties prenantes, en particulier aux patients.
Signant Health, ein führendes Unternehmen in der Generierung klinischer Prüfungsnachweise, hat sich der One Home for Sites™-Initiative von IQVIA angeschlossen. Diese Zusammenarbeit zielt darauf ab, die klinische Forschung zu vereinfachen, indem eine Plattform für den einmaligen Login bereitgestellt wird, über die Standorte auf mehrere eClinical-Technologien zugreifen können. Die SmartSignals®-Einheitsplattform von Signant, die eCOA, EDC, RTSM, eConsent und Telemedizin umfasst, wird über One Home for Sites verfügbar sein.
Sanjiv Waghmare, Chief Product Officer von Signant, äußerte seine Begeisterung für die Partnerschaft und hob hervor, dass sie mit Signants Strategie übereinstimmt, einen einheitlichen Zugang zu ihren Produkten zu bieten. Melissa Easy, VP für Kommerzialisierung bei IQVIA Technologies, begrüßte Signants Beitrag zum Aufbau eines klinischen Prüfungsökosystems der nächsten Generation, das allen Beteiligten, insbesondere den Patienten, zugutekommt.
- Signant Health joins IQVIA's One Home for Sites initiative, potentially expanding its market reach
- Partnership simplifies access to Signant's eClinical solutions for research sites
- Alignment with Signant's product strategy for unified access to their technologies
- None.
Signant Health's integration with IQVIA's One Home for Sites initiative marks a significant step towards streamlining clinical trial processes. This collaboration addresses a key pain point in the industry - the complexity of managing multiple eClinical technologies. By offering single sign-on access to various tools, including Signant's SmartSignals® Unified Platform, this move could potentially accelerate trial timelines and improve site efficiency.
From an investor's perspective, this partnership could enhance Signant's market position in the competitive eClinical solutions space. The integration with IQVIA, a major player in life sciences, may lead to increased adoption of Signant's tools, potentially driving revenue growth. However, the actual financial impact remains to be seen, as success will depend on the uptake of the One Home for Sites platform and Signant's ability to capitalize on this expanded exposure.
The integration of Signant's SmartSignals® Unified Platform into IQVIA's One Home for Sites represents a significant technological advancement in clinical trial management. This move aligns with the industry trend towards interoperability and seamless data integration. The single sign-on feature addresses a important user experience issue, potentially reducing cognitive load for clinical staff and minimizing errors associated with juggling multiple systems.
From a technical standpoint, this integration could pave the way for more standardized data formats and APIs in the eClinical space. It may also accelerate the adoption of cloud-based, modular architectures that allow for easier integration of diverse tools. However, investors should note that successful implementation will require robust data security measures and ongoing technical support to ensure smooth operation across multiple vendor platforms.
IQVIA One Home for Sites is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solution providers on a trial. Through single sign-on to a common platform, sites enjoy simplified access to trial technologies from IQVIA and other technology partners that have taken the steps to participate in One Home.
One such technology solution that will appear on the One Home for Sites platform is Signant SmartSignals® Unified Platform, itself a fully integrated solution consisting of eCOA, EDC, RTSM, eConsent, and telemedicine.
"We are very pleased to have our Unified Platform now available within One Home for Sites," said Sanjiv Waghmare, Signant's chief product officer. "IQVIA's industry-wide, collaborative approach aligns well with our overall product strategy to homogenize access to all our products through a single environment we call Signant SmartSignals® ID Portal. We applaud IQVIA's efforts to extend this philosophy by consolidating multiple solution providers into one ecosystem for easy access by sites."
"Signant Health quickly recognized the power of One Home for Sites to capture synergies across the industry and deliver a better experience to sites," said Melissa Easy, VP of Commercialization for IQVIA Technologies Digital Products and Services. "We welcome Signant to One Home and look forward to their continued contribution to building the next-generation clinical trial ecosystem that benefits all stakeholders – especially the patients we serve."
About Signant Health
Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.
About IQVIA
IQVIA (NYSE: IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Contact:
Heather Bilinski
media@signanthealth.com
+1 610.400.4141
View original content:https://www.prnewswire.com/news-releases/signant-health-expands-availability-of-its-eclinical-solutions-by-joining-iqvia-one-home-for-sites-initiative-302233398.html
SOURCE Signant Health
FAQ
What is the One Home for Sites initiative that Signant Health joined?
Which Signant Health products will be available through IQVIA's One Home for Sites?
How does the partnership between Signant Health and IQVIA (IQV) benefit clinical research sites?
What is Signant Health's strategy that aligns with IQVIA's One Home for Sites initiative?
